Patent details
EP2981263 Title: CABOZANTINIB DOSAGE FORM AND USE IN THE TREATMENT OF CANCER
Basic Information
- Publication number:
- EP2981263
- PCT Application Number:
- US2014033016
- Type:
- European Patent Granted for LU
- Legal Status:
- Lapsed
- Application number:
- EP147249098
- PCT Publication Number:
- WO2014165786
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- CABOZANTINIB DOSAGE FORM AND USE IN THE TREATMENT OF CANCER
- French Title of Invention:
- FORMULATION DE DOSAGE DU CABOZANTINIB ET UTILISATION DANS LE TRAITEMENT DU CANCER
- German Title of Invention:
- CABOZANTINIB DOSIERUNGSFORM UND VERWENDUNG ZUR BEHANDLUNG VON KREBS
- SPC Number:
Dates
- Filing date:
- 04/04/2014
- Grant date:
- 29/06/2022
- EP Publication Date:
- 10/02/2016
- PCT Publication Date:
- 09/10/2014
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 29/06/2022
- EP B1 Publication Date:
- 29/06/2022
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- 04/04/2023
- Expiration date:
- 04/04/2034
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 22/06/2022
- Name:
- Exelixis, Inc.
- Address:
- 1851 Harbor Bay Parkway, Alameda, CA 94502, United States (US)
Inventor
- Name:
- WEITZMAN, Aaron
- Address:
- United States (US)
Priority
- Priority Number:
- 201361808511 P
- Priority Date:
- 04/04/2013
- Priority Country:
- United States (US)
Classification
- IPC classification:
- A61K 9/20; A61K 31/47; A61K 31/194; A61P 35/00;
Publication
European Patent Bulletin
- Issue number:
- 202226
- Publication date:
- 29/06/2022
- Description:
- Grant (B1)
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|